Skip to main navigation Skip to search Skip to main content

Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder

  • Harirak Wanmuang
  • , Juvady Leopairut
  • , Chomsri Kositchaiwat
  • , Winai Wananukul
  • , Sukhum Bunyaratvej
  • Ramathibodi Hospital

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)

Abstract

Hepatotoxic effect related to Ganoderma lucidum (Lingzhi) mushroom powder was first described in a patient from Hong Kong in 2004. In 2005, the authors experienced a case of fatal fulminant hepatitis associated with such a preparation. Both patients had taken other therapeutic agents and traditionally boiled Lingzhi without any toxic effect. After switching to taking Lingzhi in powder form for 1-2 months, the hepatotoxic episode occurred in both patients. The toxic role of Lingzhi powder needs close monitoring in the future, especially in combination with other drugs.

Original languageEnglish
Pages (from-to)179-181
Number of pages3
JournalJournal of the Medical Association of Thailand
Volume90
Issue number1
Publication statusPublished - Jan 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Ganoderma lucidum
  • Lingzhi powder
  • Toxic hepatitis

Fingerprint

Dive into the research topics of 'Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder'. Together they form a unique fingerprint.

Cite this